MEDICUD’s Post

🔬💔 Aravive, Inc. Faces a Critical Challenge: Ovarian Cancer Trial Results Disappoint 😢📉 #Biotech #OvarianCancer #ClinicalTrials #Healthcare Aravive, Inc., a pioneering biotech company, has encountered a significant setback in its fight against ovarian cancer. The results of its phase 3 clinical trial were not what we had hoped for, causing a considerable decline in its stock price. 📉 As we stand together in the pursuit of groundbreaking medical advancements, we must acknowledge the hurdles that emerge on this challenging journey. 💪💼 Financially, Aravive finds itself at a critical juncture, with only $18 million in cash reserves remaining by the conclusion of the second quarter. 🏦 This leaves the company with a limited timeframe, spanning just a few months, to navigate its current challenges. Now, more than ever, the Aravive team needs our support, encouragement, and innovative thinking to forge a path forward. 💡 Let us rally behind Aravive's dedicated scientists, researchers, and leadership as they explore new avenues to overcome these obstacles and pave the way for a brighter, healthier future. 🌟🌈 Share this post to spread awareness and unite the scientific community in their efforts to combat ovarian cancer. Together, we can make a difference! 🤝💙 #Aravive #OvarianCancerResearch #scientificcommunity #HealthcareInnovation #togetherwecan #HopeInResearch

📰 In Brief This Week 📰 -Bionano Genomics closes a $10M direct offering with potential for $20M more from milestone-linked warrants. Funds to be used for R&D, working capital, and more. 💰🔬 #Biotech #Funding #R&D -Thermo Fisher Scientific announces a quarterly dividend of $.39 per share, payable on Oct. 15, 2024. 📈💵 #Dividends #Investments #ThermoFisher -Helio Genomics completes separation from Laboratory for Advanced Medicine. Now an independent entity, Helio focuses on commercializing its liver cancer test, HelioLiver Dx. 🧬🩸 #CancerDiagnostics #Genomics -Volition Rx partners with PharmaVentures to outlicense its oncology portfolio, including Nu.Q Cancer assays and Capture-PCR detection method. 🤝🔍 #Oncology #StrategicPartnership #Biotech -Mainz Biomed submits next-gen colorectal cancer test for FDA breakthrough device designation. Assay shows 97% sensitivity for colorectal cancer. 📑🧫 #CancerScreening #FDA #Innovation - Parse Biosciences launches CSP program with SeqMatic and Eurofins Clinical Enterprise offering single-cell products as a service. 🌐🔬 #SingleCell #BiotechServices #ParseBiosciences -MGI Australia partners with University of Queensland's CEAStAR for antimicrobial resistance testing and surveillance using DNBSeq technology. 🌊🦠 #AMR #Collaboration #MGI #BiotechNews #HealthcareInnovation #LifeSciences #MedicalResearch #TechInMedicine #InnovationInHealthcare #ScientificBreakthroughs

“Looking beyond the lampposts, looking beyond the known biology, is what Recursion’s platform promises to unlock.” ◾ The Bayer-Recursion collaboration brings together Recursion’s technology-forward and AI-leading emphasis and Bayer’s legacy of drug development. The $1.5B deal announced last October in precision oncology already has one joint project now rapidly advancing to Lead Series nomination. ◾ We are on track to complete 25 unique multimodal data packages in Q3. ◾ The Recursion operating system allows Bayer to scale up data generation, explore a large number of oncology targets simultaneously, and “do unbiased discovery.” ◾ Announced at Download Day, Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory and intuitive research environment for scientists on both sides. #techbio #ai #platform #partnership #pharma #cancer #oncology #downloadday

Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer. We are meeting the founders Marie-Agnès Doucey and Riccardo Turrini, alumni of University of Lausanne, and based at Biopôle Lausanne, in this exclusive interview for Venture Kick. Watch and be inspired: https://lnkd.in/gvBy-yDU About Calico Biosystems: Both the high attrition rate (> 95%) of therapeutics and the low response rate of patients to approved anti-cancer therapies call for a game changer in therapeutic testing. Calico Biosystems merges innovative experimental and digital approaches to assess the potency of therapeutics on patient tumours. The experimental approach uses the exclusive know-how of the founders in testing therapeutics on native patient tumours, therefore overcoming artificial models. The digital approach, based on computational modelling, predicts the most potent combinations of therapeutics to benefit patients in the clinic. Calico Biosystems' unique service provider platform will be offered to pharma & biotech companies that want to assess the efficacy of their therapeutics in pre-clinical settings, as well as hospitals and clinical trial sponsors, to identify the best combination treatment for each patient in clinics. Calico Biosystems is a 2023 alumnus of Venture Kick. Learn more: https://lnkd.in/eUMVztYk #VentureKick #SwissStartups

Champions Oncology is exhibiting at #AACR24 and presenting 9 novel research posters. Remember to stop by our new Booth #241, to learn more about our innovative platforms and services. Schedule a meeting with our team to discuss how our revolutionary platforms can transform your preclinical and clinical research: https://hubs.li/Q02kvPT90 #oncologyresearch #clinicaltrials #clinicalspecialtytesting #multiomics #bioinformatics #PDXmodels #3Dtumormodels

Immunophotonics, Inc. is grateful to National Cancer Institute (NCI) SBIR Investor Initiatives Team for providing us the opportunity to showcase our technology at the Global Life Science Partnering & Investor Conference presented by Biocom California taking place February 27 – 29, 2024 in La Jolla, California. Immunophotonics is thrilled to take part in this exclusive global partnering forum that unites senior executives, CEO’s, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Be sure to catch Lu Alleruzzo, CEO of Immunophotonics’ presenting on February 28th at 3:21 pm (PST) and see how Immunophotonics is advancing the novel concept of abscopalizing routine tumor destruction procedures. “Abscopalize It!™”  If interested in a one-on-one meeting at the event, reach out to Lu directly: https://lnkd.in/gsgMjyfZ Visit us at: www.immunophotonics.com #biotech #biotechnology #research #biopharma #drugdevelopment #lifesciences #emergingmarkets #webuildbio #antibody #startups #cancerimmunity #investors #venturecaptial #vcfunding #angleinvestors #CEO #interventionaloncology #ablation #immunooncology #cancer #immunotherapy #Immunophotonics #clinicaltrials #innovation #abscopalize_it #oncology #oncologyresearch #interventionalradiology #medicaloncology #trials #healthcareexcellence

📰 Breaking News in Biotech! 💊 SOTIO Biotech is changing the game with a massive deal! They've just struck an agreement to integrate bispecifics with their antibody-drug conjugate (ADC) capabilities. This collaboration with Biocytogen is set to cost up to $325.5 million in upfront and milestone fees 💰 Biocytogen uses transgenic mice to generate bispecific antibodies, which can be conjugated to cytotoxic payloads to create ADCs. These innovative molecules can hit two targets, which might help overcome resistance, reduce off-target toxicity, and enhance cancer-killing efficiency. Sotio has been expanding its ADC prowess for eight years through various partnerships and this latest deal is set to fill a critical gap 📊 Sotio's upcoming bispecific program aligns perfectly with their advanced pipeline, already dominated by ADC developments - watch this space 🔍👀 #SOTIOBiotech #Biocytogen #BiotechNews #Oncology #CancerTreatment #ADCTechnology #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

[#Meet2Win] 📅 May 16-17, 2024 📍 Bordeaux, France   Virginie Carrincazeaux was part of Meet2Win 2024, the European partnering convention entirely dedicated to open innovation in #oncology. Meet2win brought together leading #experts in this field. Creapharm, a Myonex company supports Pharma and Biotech companies developing #cancer therapies with: ➡ #CTSM: decades of exeriences in Clinical Trial Supply management in oncology phase I-III studies ➡ #biobanking: highly-secured storage of the most valuable research biospecimen ➡ #ATMP supply chain: with a strong expertise in ultra-cold chain management, Creapharm handles storage, packaging and logistics of the most innovative therapies, such as CAR-T cells. Thank MATWIN for arranging an event with such a high scientific level.

🚀 Unveiling Critical Oncology Insights at ESMO 2023! 🚀 The pulsating energy of innovation fills the air in Madrid, with #ESMO23 in full swing, showcasing groundbreaking progress in cancer research. It's a universe of knowledge, especially for pharma and biotech executives and enthusiasts who understand the intricacies and potential game-changers in the oncology space. 📊 To streamline your experience, we're excited to share a practical, information-rich document, simplifying the labyrinth of advancements presented at the conference! Our 'At-A-Glance' guide features: COMPANY NAME: Know the key players making waves. TICKER: For the market-savvy, track real-time market reactions. DRUG CANDIDATE: Identify the innovations that are the talk of the town. PHASE: Understand the journey of these potential therapeutics. INDICATION: Insights into specific patient populations and unmet needs being addressed. TYPE: Differentiate between the diverse therapeutic approaches. M.O.A. (Mechanism of Action): Grasp the science behind breakthroughs. This meticulous compilation is designed to be your compass, guiding you through the high-impact narratives unfolding at ESMO. By distilling complex information into a structured format, we're facilitating more than understanding; we're paving the way for industry leaders and passionate followers to engage with this data in strategic dialogues, fostering collaborative solutions. Access the attachment for these pivotal insights, and let's continue the conversation that fuels transformative oncological care. Your engagement is vital in this journey of collective growth and learning! 🔗 #OncologyInsights #Pharma #Biotech #Innovation #CollaborativeSolutions #CancerCareAdvancements